MILAN--(BUSINESS WIRE)--Allos Therapeutics, Inc. (NASDAQ:ALTH) today announced the presentation of favorable survival data from the Company’s international, randomized Phase 2b investigational study of FOLOTYN® (pralatrexate injection) relative to erlotinib in patients with Stage IIIB/IV (advanced) non-small cell lung cancer (NSCLC). In this study, patients receiving FOLOTYN had a 16 percent reduction in the risk of death compared to erlotinib in the overall (intent-to-treat) population (n=201; hazard ratio (HR)=0.84) and a 13 percent reduction in the risk of death in the primary efficacy analysis population (n=166; HR=0.87). At six months, 56 percent of patients treated with FOLOTYN were alive and 51 percent of patients treated with erlotinib were alive; at one year, 28 percent of patients treated with FOLOTYN were alive and 18 percent of patients treated with erlotinib were alive. The median overall survival (OS) time was 6.7 months for patients who received FOLOTYN and 7.0 months for patients who received erlotinib. The safety profile of FOLOTYN was consistent with that observed and reported in previous FOLOTYN solid tumor studies.
